
Gamma Delta T Cell Therapy by SL
SL BIO is advancing the frontiers of immunotherapy through the application of gamma delta (γδ) T cell technology, licensed from JY Biomedical. This platform leverages the innate immune surveillance properties of γδ T cells to explore precision-driven strategies in cancer immunology.
Gamma delta (γδ) T cells are a distinct subset of T lymphocytes with the capacity to recognize cellular stress markers independently of classical antigen presentation. This enables them to respond to abnormal cells, such as transformed or infected cells, in a manner that bridges innate and adaptive immunity. Their unique biology and broad tumor-recognition potential have made them a focus of increasing interest in next-generation immunotherapy research and investigational development.
Developed through years of focused research and manufacturing refinement, the γδ T cell platform is supported by a U.S. FDA Drug Master File filing (DMF #041080), providing a regulatory framework for quality transparency.
In collaboration with Taipei Medical University, JY Biomedical continues to investigate the role of γδ T cells through academia-industry partnerships. Preclinical research to date has demonstrated promising cytotoxic activity by unmodified γδ T cells across a range of tumor types, including brain and pancreatic.
At SL BIO, we are expanding this foundation through translational research, scientific collaboration, and disciplined development. Our goal is to responsibly advance γδ T cell platforms that contribute to the evolving landscape of immune-based oncology innovation.
Animal Model

Ongoing Academic Cooperation Project


Taipei Medical University
Ph.D. Program in Medical Neuroscience
Taipei Medical University Hospital
Neurosurgery

Patent

U.S. Food and Drug Administration
DMFs List of Drug Master Files
